Traders Purchase High Volume of Call Options on Sanofi (NYSE:SNY)

Sanofi SA (NYSE:SNY) was the recipient of some unusual options trading on Wednesday. Stock traders bought 12,970 call options on the stock. This represents an increase of 2,258% compared to the average daily volume of 550 call options.

Shares of NYSE SNY opened at $46.08 on Friday. The stock has a market capitalization of $116.19 billion, a PE ratio of 14.72, a P/E/G ratio of 2.41 and a beta of 0.67. The company has a quick ratio of 0.85, a current ratio of 1.22 and a debt-to-equity ratio of 0.40. The firm has a fifty day moving average of $46.16 and a 200-day moving average of $43.91. Sanofi has a 52-week low of $40.00 and a 52-week high of $47.47.

Sanofi (NYSE:SNY) last issued its earnings results on Thursday, October 31st. The company reported $1.07 earnings per share for the quarter, topping the consensus estimate of $0.96 by $0.11. Sanofi had a return on equity of 18.18% and a net margin of 12.20%. The business had revenue of $10.56 billion for the quarter, compared to analyst estimates of $10.62 billion. Equities research analysts expect that Sanofi will post 3.1 EPS for the current fiscal year.

Several analysts have commented on SNY shares. JPMorgan Chase & Co. restated a “neutral” rating on shares of Sanofi in a report on Monday, October 14th. UBS Group raised shares of Sanofi from a “neutral” rating to a “buy” rating in a research note on Wednesday, August 14th. Argus reiterated a “buy” rating and set a $52.00 price objective (up from $50.00) on shares of Sanofi in a report on Wednesday, November 13th. Morgan Stanley raised shares of Sanofi from an “equal” rating to a “weight” rating in a research report on Friday, September 20th. Finally, Sanford C. Bernstein began coverage on shares of Sanofi in a report on Tuesday, September 3rd. They issued an “outperform” rating and a $52.00 target price for the company. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $50.33.

In related news, major shareholder Sanofi sold 172,904 shares of the stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $281.15, for a total transaction of $48,611,959.60. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 1.00% of the company’s stock.

A number of large investors have recently made changes to their positions in the business. Ibex Wealth Advisors purchased a new stake in shares of Sanofi during the 2nd quarter worth about $25,000. Heritage Wealth Advisors raised its holdings in Sanofi by 141.2% in the second quarter. Heritage Wealth Advisors now owns 603 shares of the company’s stock valued at $26,000 after buying an additional 353 shares during the period. Prestige Wealth Management Group LLC acquired a new position in Sanofi during the second quarter valued at approximately $37,000. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA acquired a new position in Sanofi during the third quarter valued at approximately $37,000. Finally, Stonebridge Capital Advisors LLC purchased a new stake in Sanofi during the second quarter worth approximately $41,000. Institutional investors own 7.04% of the company’s stock.

About Sanofi

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Read More: Analyst Ratings

Receive News & Ratings for Sanofi Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Sanofi and related companies with’s FREE daily email newsletter.